General
Preferred name
OMACETAXINE MEPESUCCINATE
Synonyms
Homoharringtonine ()
HHT ()
Ceflatonin ()
Myelostat ()
CGX-635 ()
Synribo ()
H1196 ()
Cephalotaxine, 3-[4-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate] ()
Homoharringtonine (CGX-635) ()
Omacetaxine mepesuccinate, HHT, Myelostat, NSC 141633 ()
Omapro ()
NSC-141633 ()
Homoharringtonin ()
P&D ID
PD003333
CAS
26833-87-4
Tags
nuisance
natural product
drug
available
Approved by
FDA
First approval
2012
2009
Drug Status
investigational
approved
Drug indication
Chronic myeloid leukaemia
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS The pharmacodynamics of homoharringtonine is not fully understood. It is known that homoharringtonine is involved; with protein synthesis inhibition and this leads to its antineoplastic activity.;
MOA Homoharringtonine inhibits protein synthesis by not directly binding to Bcr-Abl. It binds to the A-site cleft in the large ribosomal subunit, which affects chain elongation and prevents protein synthesis.; ;
INDICATION Used in patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML. ; ;
METABOLISM Homoharringtonine has undergoes little hepatic metabolism and is mostly metabolized to 4’-DMHHT by plasma esterase hydrolysis.; ;
DESCRIPTION Omacetaxine mepesuccinate is a semi-synthetic derivative of the alkaloid cephalotaxine from Cephalotaxus harringtonia. Note that this compound is represented on Drugbank with slightly different stereochemistry by the entry DB04865. (GtoPdb)
DESCRIPTION inhibitor of protein translation by preventing protein elongation (Informer Set)
DESCRIPTION Arrests cell cycle in G1 phase (Tocris Bioactive Compound Library)
DESCRIPTION Inhibitor of protein synthesis. Antileukemic agent (Tocriscreen Total)
Cell lines
8
Organisms
1
Compound Sets
24
Cayman Chemical Bioactives
14631
ChEMBL Approved Drugs
CHEMBL46286
ChEMBL Drugs
CHEMBL46286
Drug Repurposing Hub
DrugBank
DB04865
DrugBank Approved Drugs
DB04865
DrugCentral
4677
DrugCentral Approved Drugs
4677
DrugMAP
DMPU2WX
DrugMAP Approved Drugs
DMPU2WX
EU-OPENSCREEN Bioactive Compound Library
EOS101430
Guide to Pharmacology
7454
Informer Set
375219
JUMP-Target 1 Compound Set
285033
MedChem Express Bioactive Compound Library
HY-14944
Natural product-based probes and drugs
NIH Approved Oncology Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
Nuisance compounds in cellular assays
ReFrame library
Selleckchem Bioactive Compound Library
homoharringtonine
TargetMol Bioactive Compound Library
T3380
Tocris Bioactive Compound Library
1416
Tocriscreen Total
External IDs
35
Properties
(calculated by RDKit )
Molecular Weight
545.26
Hydrogen Bond Acceptors
10
Hydrogen Bond Donors
2
Rotatable Bonds
9
Ring Count
5
Aromatic Ring Count
1
cLogP
2.58
TPSA
123.99
Fraction CSP3
0.66
Chiral centers
4.0
Largest ring
7.0
QED
0.45
Structural alerts
1
Protein disruption
Translation inhibition
Nuisance compounds in cellular assays
Related compounds
Custom attributes
(extracted from source data)
Compound status
FDA
Pathway
JAK/STAT Signaling
Stem Cells
Stem Cell/Wnt
Target
STAT3
RPL3
STAT
Primary Target
DNA, RNA and Protein Synthesis
MOA
Inhibitor
"Translation inhibitor
treatment of orphan leukemia
Elongation inhibitor
Treatment of orphan leukemia"
Translation inhibitor
protein synthesis inhibitor
Member status
member
Indication
chronic myeloid leukemia (CML)
Biosynthetic Origin
Alkaloid
Therapeutic Indication
Anticancer
Source data